Botox-maker Allergan just picked up a regenerative medicine company for $2.9 billion
AP
The purchase is Allergan's first step into regenerative medicine, which it plans to apply to the plastic surgery space.
"The acquisition of LifeCell is both strategically and financially compelling to Allergan and serves as our entry point into regenerative medicine as we create a world-class aesthetic and regenerative medicine business in plastic surgery," Allergan CEO Brent Saunders said in a statement Tuesday.
Allergan was slightly down Tuesday morning on the news.
The deal closes out a year of deals for Botox-maker Allergan. In the month of September and beginning of October, Allergan committed $3.67 billion to acquisitions and investments, followed by more deals later in October and in November.
LifeCell's expected to generate $450 million in revenue in 2016, Allergan noted in a release. Its main products are tissue materials that are used in breast reconstruction and abdominal wall surgeries.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- An Ambani disruption in OTT: At just ₹1 per day, you can now enjoy ad-free content on JioCinema
- Reliance gets thumbs-up from S&P, Fitch as strong earnings keep leverage in check
- Realme C65 5G with 5,000mAh battery, 120Hz display launched starting at ₹10,499
- 8 Fun things to do in Kasol
- SC rejects pleas seeking cross-verification of votes cast using EVMs with VVPAT
- Ultraviolette F77 Mach 2 electric sports bike launched in India starting at ₹2.99 lakh